Clinicopathological significance of S100 protein expression in cholangiocarcinoma

Journal of Gastroenterology and Hepatology (Australia)

Volumn 28, Issue 8, 2013, Pages 1422-1429

  Sato, Yasunori ^a   Harada, Kenichi ^a   Sasaki, Motoko ^a   Nakanuma, Yasuni ^a  

^a KANAZAWA UNIVERSITY GRADUATE SCHOOL OF MEDICAL SCIENCE   (Japan)

Author keywords

Biliary intraepithelial neoplasia; Cholangiocarcinoma; S100 protein

Indexed keywords

CALVASCULIN; PROTEIN S 100; PROTEIN S 100A2; PROTEIN S 100A6; PROTEIN S 100P; UNCLASSIFIED DRUG;

ADENOCARCINOMA; ADULT; AGED; ARTICLE; BILE; BILE DUCT CARCINOMA; CANCER STAGING; CARCINOGENESIS; CLINICAL ARTICLE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; MALE; PRIORITY JOURNAL; PROCEDURES; PROTEIN EXPRESSION; SURVIVAL RATE;

EID: 84880665353     PISSN: 08159319     EISSN: 14401746     Source Type: Journal    
DOI: 10.1111/jgh.12247     Document Type: Article

References (37)

1. Nakanuma Y, Sasaki M, Sato Y, Ren X, Ikeda H, Harada K. Multistep carcinogenesis of perihilar cholangiocarcinoma arising in the intrahepatic large bile ducts. World. J. Hepatol. 2009; 1: 35-42.
2. Zen Y, Aishima S, Ajioka Y etal. Proposal of histological criteria for intraepithelial atypical/proliferative biliary epithelial lesions of the bile duct in hepatolithiasis with respect to cholangiocarcinoma: preliminary report based on interobserver agreement. Pathol. Int. 2005; 55: 180-188.
3. Zen Y, Adsay NV, Bardadin K etal. Biliary intraepithelial neoplasia: an international interobserver agreement study and proposal for diagnostic criteria. Mod. Pathol. 2007; 20: 701-709.
4. Itatsu K, Zen Y, Ohira S etal. Immunohistochemical analysis of the progression of flat and papillary preneoplastic lesions in intrahepatic cholangiocarcinogenesis in hepatolithiasis. Liver Int. 2007; 27: 1174-1184.
5. Sasaki M, Yamaguchi J, Itatsu K, Ikeda H, Nakanuma Y. Over-expression of polycomb group protein EZH2 relates to decreased expression of p16 INK4a in cholangiocarcinogenesis in hepatolithiasis. J. Pathol. 2008; 215: 175-183.
6. Nakanishi Y, Zen Y, Kondo S, Itoh T, Itatsu K, Nakanuma Y. Expression of cell cycle-related molecules in biliary premalignant lesions: biliary intraepithelial neoplasia and biliary intraductal papillary neoplasm. Hum. Pathol. 2008; 39: 1153-1161.
7. Sato Y, Harada K, Sasaki M, Yasaka T, Nakanuma Y. Heat shock proteins 27 and 70 are potential biliary markers for the detection of cholangiocarcinoma. Am. J. Pathol. 2012; 180: 123-130.
8. Ohuchida K, Mizumoto K, Miyasaka Y etal. Over-expression of S100A2 in pancreatic cancer correlates with progression and poor prognosis. J. Pathol. 2007; 213: 275-282.
9. Biankin AV, Kench JG, Colvin EK etal. Expression of S100A2 calcium-binding protein predicts response to pancreatectomy for pancreatic cancer. Gastroenterology 2009; 137: 558-568, 568.e1-11.
10. Mahon PC, Baril P, Bhakta V etal. S100A4 contributes to the suppression of BNIP3 expression, chemoresistance, and inhibition of apoptosis in pancreatic cancer. Cancer Res. 2007; 67: 6786-6795.
11. Ikenaga N, Ohuchida K, Mizumoto K etal. S100A4 mRNA is a diagnostic and prognostic marker in pancreatic carcinoma. J. Gastrointest. Surg. 2009; 13: 1852-1858.
12. Fabris L, Cadamuro M, Moserle L etal. Nuclear expression of S100A4 calcium-binding protein increases cholangiocarcinoma invasiveness and metastasization. Hepatology 2011; 54: 890-899.
13. Kim J, Kim J, Yoon S etal. S100A6 protein as a marker for differential diagnosis of cholangiocarcinoma from hepatocellular carcinoma. Hepatol. Res. 2002; 23: 274-286.
14. Ohuchida K, Mizumoto K, Ishikawa N etal. The role of S100A6 in pancreatic cancer development and its clinical implication as a diagnostic marker and therapeutic target. Clin. Cancer Res. 2005; 11: 7785-7793.
15. Ohuchida K, Mizumoto K, Egami T etal. S100P is an early developmental marker of pancreatic carcinogenesis. Clin. Cancer Res. 2006; 12: 5411-5416.
16. Lin F, Shi J, Liu H etal. Diagnostic utility of S100P and von Hippel-Lindau gene product (pVHL) in pancreatic adenocarcinoma-with implication of their roles in early tumorigenesis. Am. J. Surg. Pathol. 2008; 32: 78-91.
17. Aishima S, Fujita N, Mano Y etal. Different roles of S100P overexpression in intrahepatic cholangiocarcinoma: carcinogenesis of perihilar type and aggressive behavior of peripheral type. Am. J. Surg. Pathol. 2011; 35: 590-598.
18. Komuta M, Govaere O, Vandecaveye V etal. Histological diversity in cholangiocellular carcinoma reflects the different cholangiocyte phenotypes. Hepatology 2012; 55: 1876-1888.
19. Sobin LH, Wittekind C. International Union Against Cancer (UICC). TNM Classification of Malignant Tumors, 6th edn. New York: Wiley-Liss, 2002.
20. Jiang H, Hu H, Tong X, Jiang Q, Zhu H, Zhang S. Calcium-binding protein S100P and cancer: mechanisms and clinical relevance. J. Cancer Res. Clin. Oncol. 2001; 138: 1-9.
21. Arumugam T, Logsdon CD. S100P: a novel therapeutic target for cancer. Amino Acids 2011; 41: 893-899.
22. Crnogorac-Jurcevic T, Missiaglia E, Blaveri E etal. Molecular alterations in pancreatic carcinoma: expression profiling shows that dysregulated expression of S100 genes is highly prevalent. J. Pathol. 2003; 201: 63-74.
23. Logsdon CD, Simeone DM, Binkley C etal. Molecular profiling of pancreatic adenocarcinoma and chronic pancreatitis identifies multiple genes differentially regulated in pancreatic cancer. Cancer Res. 2003; 63: 2649-2657.
24. Naidoo K, Jones R, Dmitrovic B etal. Proteome of formalin-fixed paraffin-embedded pancreatic ductal adenocarcinoma and lymph node metastases. J. Pathol. 2012; 226: 756-763.
25. Bournet B, Pointreau A, Souque A etal. Gene expression signature of advanced pancreatic ductal adenocarcinoma using low density array on endoscopic ultrasound-guided fine needle aspiration samples. Pancreatology 2012; 12: 27-34.
26. Dim DC, Jiang F, Qiu Q etal. The usefulness of S100P, mesothelin, fascin, prostate stem cell antigen, and 14-3-3 sigma in diagnosing pancreatic adenocarcinoma in cytological specimens obtained by endoscopic ultrasound guided fine-needle aspiration. Diagn. Cytopathol. 2011. DOI: 10.1002/dc.21684.
27. Kosarac O, Takei H, Zhai QJ, Schwartz MR, Mody DR. S100P and XIAP expression in pancreatic ductal adenocarcinoma: potential novel biomarkers as a diagnostic adjunct to fine needle aspiration cytology. Acta Cytol. 2011; 55: 142-148.
28. Deng H, Shi J, Wilkerson M, Meschter S, Dupree W, Lin F. Usefulness of S100P in diagnosis of adenocarcinoma of pancreas on fine-needle aspiration biopsy specimens. Am. J. Clin. Pathol. 2008; 129: 81-88.
29. Dowen SE, Crnogorac-Jurcevic T, Gangeswaran R etal. Expression of S100P and its novel binding partner S100PBPR in early pancreatic cancer. Am. J. Pathol. 2005; 166: 81-92.
30. Nakata K, Nagai E, Ohuchida K etal. S100P is a novel marker to identify intraductal papillary mucinous neoplasms. Hum. Pathol. 2010; 41: 824-831.
31. Nakanuma Y. A novel approach to biliary tract pathology based on similarities to pancreatic counterparts: is the biliary tract an incomplete pancreas? Pathol. Int. 2010; 60: 419-429.
32. Schmidt MT, Himmelfarb EA, Shafi H, Lin F, Xu H, Wang HL. Use of IMP3, S100P, and pVHL immunopanel to aid in the interpretation of bile duct biopsies with atypical histology or suspicious for malignancy. Appl. Immunohistochem. Mol. Morphol. 2012; 20: 478-487.
33. Levy M, Lin F, Xu H, Dhall D, Spaulding BO, Wang HL. S100P, von Hippel-Lindau gene product, and IMP3 serve as a useful immunohistochemical panel in the diagnosis of adenocarcinoma on endoscopic bile duct biopsy. Hum. Pathol. 2010; 41: 1210-1219.
34. Hamada S, Satoh K, Hirota M etal. Calcium-binding protein S100P is a novel diagnostic marker of cholangiocarcinoma. Cancer Sci. 2011; 102: 150-156.
35. Jamieson NB, Carter CR, McKay CJ, Oien KA. Tissue biomarkers for prognosis in pancreatic ductal adenocarcinoma: a systematic review and meta-analysis. Clin. Cancer Res. 2011; 17: 3316-3331.
36. Sato Y, Harada K, Itatsu K etal. Epithelial-mesenchymal transition induced by transforming growth factor-beta1/Snail activation aggravates invasive growth of cholangiocarcinoma. Am. J. Pathol. 2010; 177: 141-152.
37. Tyson GL, El-Serag HB. Risk factors for cholangiocarcinoma. Hepatology 2011; 54: 173-184.